Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
| ▸ | TOP2A | P11388 | 3/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23564249 | 0.83 | HRH3 (0.38) | BACE1BACE2HRH3LPLLIPG | |
| SCHEMBL27182499 | 0.82 | LPL (0.35) | PRMT5WDR77BACE1BACE2HRH3 | |
| SCHEMBL29804053 | 0.77 | GLS (0.39) | HRH3TOP2AHRH4 | |
| SCHEMBL23533600 | 0.77 | GLS (0.39) | HRH3TOP2AHRH4 | |
| SCHEMBL30051494 | 0.74 | LPL (0.36) | PRMT5WDR77BACE1BACE2LPL | |
| SCHEMBL31316806 | 0.74 | HRH3 (0.36) | HRH3TOP2AHRH4 | |
| SCHEMBL6287405 | 0.73 | CA2 (0.36) | BACE1LPLLIPGHIF1AROCK1 | |
| SCHEMBL31394338 | 0.73 | TDP1 (0.47) | LPLLIPGROCK1 | |
| SCHEMBL29175434 | 0.72 | HRH3 (0.48) | HRH3LPLLIPGHRH4ROCK1 | |
| SCHEMBL3289662 | 0.71 | TOP2A (0.35) | HRH3TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | PRMT5 589/4885WDR77 2040/4885BACE1 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.